Browse News
Filter News
Found 544,027 articles
-
Biotech and pharma companies from across Europe and Asia provide updates on pipeline and business activities.
-
Arizona is not exactly the first place one thinks of when it comes to the life sciences. But, like many states and municipalities, Arizona and Phoenix, Arizona, are working hard to grow the life science industry.
-
Exclusive: Sweden’s Lobsor Gains U.S. Patent for Its Advanced Parkinson’s Disease Treatment
3/21/2019
Privately-held Swedish pharmaceutical company Lobsor Pharmaceuticals AB is eying the U.S. market for a potential treatment for neurodegenerative diseases such as Parkinson’s disease. -
One year after spinning out from AstraZeneca’s MedImmune, Viela Bio is already anticipating filing a Biologics License Application with the U.S. Food and Drug Administration for its lead asset, inebilizumab.
-
BioInvent Unveils Broad Anti-TNFR2 Program to Treat Solid Tumors
3/21/2019
Proprietary n-CoDeR® & F.I.R.S.T.™ platforms yield wealth of candidates
-
NextLevel Health Partners, Inc., Announces The Creation Of The Complete Health Advisory Council
3/21/2019
Leading Providers and Community Partners Throughout Chicago and Cook County Collaborate to Address Social Determinants That Impede Holistic, Quality Health Care
-
Samsung Bioepis Announces Three-year Follow-up Data for Biosimilar ONTRUZANT® (trastuzumab) in Early or Locally Advanced HER2-positive Breast Cancer
3/21/2019
Three-year follow-up data show comparable overall survival between biosimilar ONTRUZANT® (trastuzumab) and reference medicine HERCEPTIN®i (trastuzumab)ii in early and locally advanced HER2-positive breast cancer
-
Orexo Publishes the Annual Report for 2018
3/21/2019
Orexo's Annual Report, including the Sustainability Report, for the 2018 fiscal year has been published and can be downloaded on the company's website, www.orexo.com.
-
Is the Nation's Blood Supply as Important as the Opioid Crisis? Top Federal Health Officials and Blood Banking Leaders Say Yes
3/21/2019
US health official and Bloodworks Northwest CEO tell Congress the need for more young donors has never been greater
-
Rare Diseases: PKU GOLIKE® Debuts in Germany
3/21/2019
PKU GOLIKE®, the brand new generation of Phenylalanine-free medical food for Phenylketonuria dietary management, is now available in Germany and Austria, promoted and distributed directly by APR Applied Pharma Research s.a. through its local subsidiary, APR Deutschland.
-
Research from XJTLU advances RNA modification mapping
3/21/2019
Researchers from Xi'an Jiaotong-Liverpool University have completed a high-resolution prediction of the whole-transcriptome m6A RNA modification, successfully creating the world's most accurate map of the m6A epitranscriptome.
-
Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing
3/21/2019
Aerie Pharmaceuticals, Inc. announced the commencement of patient dosing in its Phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA to support potential regulatory submission of netarsudil ophthalmic solution in Japan.
-
Lead Pharma Announces Start of Phase I Clinical Trials with SAR441169 Candidate Treatment for Psoriasis
3/21/2019
Sanofi, Lead Pharma’s collaborative partner in the development of SAR441169, successfully initiated first human dosing with this novel RORγt Inverse Agonist candidate treatment
-
Novocure’s Chief Science Officer Retires after 17 Years of Service
3/21/2019
Novocure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, effective May 1, 2019.
-
Hansa Biopharma Announces Selection of NiceR Lead Candidate
3/21/2019
Next Generation Enzyme Technology Platform Offers Potential for Repeat Dosing
-
Adlai Nortye Receives NMPA Approval for Pelareorep (AN1004) in China to Initiate Phase III Clinical Trials
3/21/2019
Adlai Nortye Ltd., a global clinical-stage biopharmaceutical company, announced that it has received a clearance from the National Medical Products Administration of China for initiating the open-label, randomized, multicenter, global phase III clinical trial for pelareorep in combination with paclitaxel in patients with advanced/ metastatic breast cancer in China.
-
Gelesis Announces Three Presentations at Annual Endocrine Society Meeting
3/21/2019
Gelesis announced the Company will deliver three poster presentations at ENDO, the Endocrine Society Annual Meeting, held in New Orleans from March 23-26.
-
Laboratoire Synbionyme to Bring its Probiotic Skincare Products to Health & Wellness Conference in Orlando March 31-April 3
3/21/2019
Laboratoire Synbionyme, a Paris-based company, will bring its next-generation skincare products to the 2019 Weight Management, Sports Nutrition, Vitamin & Hemp Solutions EPPS conference March 31-April 3 in Orlando.
-
Innovus Pharmaceuticals Reports Preliminary Annual 2018 Net Revenue of $24 Million
3/21/2019
Preliminary Annual Revenue Increase by 2.7x Compared to Prior Year
-
Muno-Vax Biotechnologies Promotes National Nutrition Month in March
3/21/2019
Muno-Vax Biotechnologies this week urged everyone to re-evaluate their health habits during National Nutrition Month.